1414 related articles for article (PubMed ID: 30846338)
41. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
44. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
[TBL] [Abstract][Full Text] [Related]
45. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
[TBL] [Abstract][Full Text] [Related]
46. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Thonsgaard S; Prickett TCR; Hansen LH; Wewer Albrechtsen NJ; Andersen UØ; Terzic D; Plomgaard P; Gustafsson F; Goetze JP; Mark PD
Clin Chem; 2022 May; 68(5):713-720. PubMed ID: 35175317
[TBL] [Abstract][Full Text] [Related]
47. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
48. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
49. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Chrysant SG
J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
[TBL] [Abstract][Full Text] [Related]
51. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
Mogensen UM; Køber L; Jhund PS; Desai AS; Senni M; Kristensen SL; Dukát A; Chen CH; Ramires F; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Solomon SD; Swedberg K; Packer M; McMurray JJV;
Eur J Heart Fail; 2018 Mar; 20(3):514-522. PubMed ID: 29193563
[TBL] [Abstract][Full Text] [Related]
52. Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan.
Dillon EM; Wei SD; Gupta DK; Nian H; Rodibaugh BS; Bachmann KN; Naftilan AJ; Stevenson LW; Brown NJ
J Card Fail; 2021 Nov; 27(11):1231-1239. PubMed ID: 34133968
[TBL] [Abstract][Full Text] [Related]
53. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
Berardi C; Braunwald E; Morrow DA; Mulder HS; Duffy CI; O'Brien TX; Ambrosy AP; Chakraborty H; Velazquez EJ; DeVore AD;
JACC Heart Fail; 2020 Oct; 8(10):859-866. PubMed ID: 32919915
[TBL] [Abstract][Full Text] [Related]
54. Health-Related Quality of Life Outcomes in PARADIGM-HF.
Lewis EF; Claggett BL; McMurray JJV; Packer M; Lefkowitz MP; Rouleau JL; Liu J; Shi VC; Zile MR; Desai AS; Solomon SD; Swedberg K
Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28784687
[TBL] [Abstract][Full Text] [Related]
55. Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Lippi G; Sanchis-Gomar F
Int J Cardiol; 2016 Sep; 219():111-4. PubMed ID: 27317994
[TBL] [Abstract][Full Text] [Related]
56. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
57. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Vasquez N; Carter S; Grodin JL
Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
[TBL] [Abstract][Full Text] [Related]
58. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
[TBL] [Abstract][Full Text] [Related]
59. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
Sokos GG; Raina A
Vasc Health Risk Manag; 2020; 16():41-51. PubMed ID: 32021227
[TBL] [Abstract][Full Text] [Related]
60. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Chin KL; Zomer E; Wang BH; Liew D
Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
